Autoimmune Bullous Dermatological Disorders

Autoimmune bullous disorders constitute a group of rare but potentially life‐threatening dermatological conditions marked by the production of pathogenic autoantibodies directed against structural proteins of the epidermis or dermoepidermal junction. They are broadly classified according to their level of blister formation into suprabasal (pemphigus group) or subepidermal (pemphigoid group) diseases. The most common subepidermal example is bullous pemphigoid, primarily affecting older individuals, which manifests as tense vesicles and bullae on an erythematous base, often accompanied by intense pruritus. Pathogenesis centres on autoantibody binding to hemidesmosomal proteins (notably BP180 and BP230), activation of complement, and recruitment of inflammatory cells leading to dermal–epidermal separation. Pemphigus vulgaris is characterised by suprabasal acantholysis resulting from autoantibodies against desmoglein 1 and 3. Clinical management requires accurate diagnosis through histopathology and immunofluorescence, with treatment strategies encompassing systemic immunosuppression, targeted biologics and adjuvant therapies to mitigate long-term morbidity and mortality. Advances in understanding genetic predisposition, comorbid associations—particularly with neurological and metabolic disorders—and environmental triggers have refined risk stratification and therapeutic decision‐making. Emerging approaches in precision medicine aim to balance efficacy against the risks of immunosuppression, especially in an ageing population with multiple comorbidities.

Research from Nature Portfolio

Recent single-cell transcriptomic analysis has unveiled the complexity of immune–stromal interactions in bullous pemphigoid. By profiling individual cells from lesional skin, investigators have identified Th2 lymphocytes, dendritic cells and fibroblasts as central to a pathogenic loop driven by the IL13–IL13RA1 axis. Binding of IL-13 to its receptor on fibroblasts and dendritic cells upregulates mediators such as PLA2G2A and CCL17, which in turn enhance Th2 cell activation and autoantibody production against BP180. This work provides a high-resolution map of cellular crosstalk, illuminating novel targets for interrupting the cycle of inflammation and tissue damage in subepidermal blistering disease.

Autoimmune Bullous Dermatological Disorders publication trend

The graph below shows the total number of articles in autoimmune bullous dermatological disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Autoantibody: An antibody produced by the immune system that erroneously targets the body’s own proteins.

Hemidesmosome: A multiprotein complex anchoring basal keratinocytes to the basement membrane.

Single-cell RNA sequencing: A technique that profiles gene expression at the level of individual cells.

Th2 cell: A subset of T helper lymphocytes that secrete cytokines such as interleukin-4 and interleukin-13, promoting antibody responses.

PLA2G2A and CCL17: Molecules involved in inflammatory signalling; PLA2G2A is a secreted phospholipase, CCL17 is a chemokine attracting Th2 cells.

References

1. Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease. Nature Communications (2024).
2. Mechanisms of Autoantibody-Induced Pathology. Frontiers in Immunology (2017).
3. The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations. Frontiers in Medicine (2018).
4. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. The Lancet (2017).